11 April 2025
11 April 2025
The FDA has announced plans to phase out animal testing in the development of monoclonal antibodies and other drugs.
The twice daily tablet represents a significant step forward for patients with advanced breast cancer.
The biotech has launched a strategic review to consider options, including a possible sale, following shareholder pressure.
The company’s biosimilar oncology portfolio in the US also includes Fulphila and Ogivri.
The grant will be distributed in three $1m tranches, with the first payment scheduled for 1 May 2025.
Takeda China handles the therapy’s commercialisation in mainland China, Macau and Hong Kong.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
